UPLYFT for Lymphoma
Trial Summary
What is the purpose of this trial?
The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the UPLYFT treatment for lymphoma?
Research shows that fear of cancer recurrence is a common issue for cancer patients, including those with lymphoma, and addressing this fear can improve quality of life. Similar treatments, like ConquerFear and FoRtitude, have been effective in reducing fear of recurrence in cancer survivors, suggesting that UPLYFT may also help lymphoma patients manage their fears.12345
Research Team
Oreofe O Odejide, MD, PhD
Principal Investigator
Oreofe_Odejide@dfci.harvard.edu
Eligibility Criteria
This trial is for adults over 18 who have been treated for lymphoma and are in remission but still experience significant fear of cancer recurrence. They must be within 3 to 24 months post-treatment, have access to a computer, and not have other untreated major psychiatric disorders or concurrent malignancies.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Development
Development of the UPLYFT program based on feedback from clinicians and a field test with lymphoma survivors
Intervention
Lymphoma survivors participate in the finalized UPLYFT program consisting of 6 weekly sessions
Follow-up
Participants are monitored for changes in psychological inflexibility, depression, fear of cancer recurrence, quality of life, and anxiety
Treatment Details
Interventions
- UPLYFT
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
American Society of Hematology
Collaborator